Authors

Latest:

Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Neal D. Shore, MD, FACS, Carolina Urologic Research Center

Latest:

Rapid Readouts: Phase 3 HERO Trial

Neal Dave

Latest:

The Role of Positive Quality Interventions

Neal Dave, PharmD, Texas Oncology, discusses the role of positive quality interventions (PQI).

Neal E. Ready, MD, PhD, Duke University Medical Center

Latest:

Dr. Ready on Leveraging Nivolumab/Ipilimumab Plus Chemotherapy in NSCLC

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.

Neal J. Weinreb, MD

Latest:

Dr. Weinreb on the Different Roles in a Gaucher Diagnosis

Dr. Neal Weinreb, from University Research Foundation for Lysosomal Storage Diseases, on the Different Roles in a Gaucher Diagnosis

Neal P. Christiansen, MD

Latest:

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Neal Shore, MD, FACS

Latest:

Dr Shore on the Rationale for the Duravelo-2 Trial in Metastatic Urothelial Cancer

Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.

Neal Shore, MD, FACS, Carolina Urologic Research Center

Neal Young, MD

Latest:

Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

Neehar Parikh, MD

Latest:

Dr. Parikh on Future Research Directions in Hepatitis C-Related HCC

Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.

Neelima Denduluri, MD

Latest:

Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer

Neelima Denduluri, MD, shares treatment approaches in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

Neeraj Agarwal, MD

Latest:

Key Takeaways on Updates in Bladder Cancer

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Neeraj Agarwal, MD, Hunstman Cancer Institute

Neeraj Agarwal, MD, Huntsman Cancer Institute

Latest:

Advanced Clear Cell Renal Cell Carcinoma: Putting Advances Into Practice

Neeraj Agarwal, MD, MS, Huntsman Cancer Institute

Neeta Somaiah, MD

Latest:

Dr Somaiah on the Peak Trial in GIST

Neeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.

Neeta Somaiah, MD, MD Anderson Cancer Center

Neha Mehta-Shah, MD, Washington University School of Medicine in St. Louis

Neil D. Gross, MD, FACS

Latest:

Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.